Abstract：
We recently developed compound FC-7269 for targeting the Molluscum contagiosum virus processivity factor (mD4) and demonstrated its ability to inhibit viral processive DNA synthesis in vitro and cellular infection of an mD4-dependent virus (Antiviral Res 211, 2023,105520). However, despite a thorough medicinal chemistry campaign we were unable to generate a potent second analog as a requisite for drug development. We overcame this impasse, by conjugating a short hydrophobic trivaline peptide to FC-7269 to produce FC-TriVal-7269 which significantly increased antiviral potency and reduced cellular toxicity.
摘要：
我们最近开发了化合物FC-7269，用于靶向传染性软疣病毒持续性因子（mD4），并证明了其在体外抑制病毒持续性DNA合成和mD4依赖性病毒的细胞感染的能力（抗病毒Res211,2023,105520）。然而,尽管进行了彻底的药物化学运动，但我们仍无法生成有效的第二类似物作为药物开发的必要条件。我们克服了僵局,通过将短的疏水性三缬氨酸肽与FC-7269缀合以产生FC-TriVal-7269,其显着增加抗病毒效力并降低细胞毒性。
